Kinga Panuciak

Ms. Kinga Panuciak

Medical University of Lublin
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JLJan Lejman
Jan Lejman
KPKinga Panuciak
Kinga Panuciak
ENEmilia Nowicka
Emilia Nowicka
AMAngelika Mastalerczyk
Angelika Mastalerczyk
KWKatarzyna Wojciechowska
Katarzyna Wojciechowska
MLMonika Lejman
Monika Lejman
Gene therapy is defined as the administration of genetic material to modify, manipulate gene expression or alter the properties of living cells for therapeutic purposes. Recent advances and improvements in this field have led to many breakthroughs in the treatment of various diseases. As a result, there has been an increasing interest in the use of these therapies to treat motor neuron diseases (MNDs), for which many potential molecular targets have been discovered. MNDs are neurodegenerative disorders that, in their most severe forms, can lead to respiratory failure and death, for instance, spinal muscular atrophy (SMA) or amyotrophic lateral sclerosis (ALS). Despite the fact that SMA has been known for many years, it is still one of the most common genetic diseases causing infant mortality. The introduction of drugs based on ASOs—nusinersen; small molecules—risdiplam; and replacement therapy (GRT)—Zolgensma has shown a significant improvement in both event-free survival and the quality of life of patients after using these therapies in the available trial results. Although there is still no drug that would effectively alleviate the course of the disease in ALS, the experience gained from SMA gene therapy gives hope for a positive outcome of the efforts to produce an effective and safe drug. The aim of this review is to present current progress and prospects for the use of gene therapy in the treatment of both SMA and ALS.

2 January 2022 in Cells
Verified
Journal Article
Open access
PDF file
KPKinga Panuciak
Kinga Panuciak
MMMikołaj Margas
Mikołaj Margas
KMKarolina Makowska
Karolina Makowska
MLMonika Lejman
Monika Lejman
Pediatric cancers predominantly constitute lymphomas and leukemias. Recently, our knowledge and awareness about genetic diversities, and their consequences in these diseases, have greatly expanded. Modern solutions are focused on mobilizing and impacting a patient’s immune system. Strategies to stimulate the immune system, to prime an antitumor response, are of intense interest. Amid those types of therapies are chimeric antigen receptor T (CAR-T) cells, bispecific antibodies, and antibody–drug conjugates (ADC), which have already been approved in the treatment of acute lymphoblastic leukemia (ALL)/acute myeloid leukemia (AML). In addition, immune checkpoint inhibitors (ICIs), the pattern recognition receptors (PRRs), i.e., NOD-like receptors (NLRs), Toll-like receptors (TLRs), and several kinds of therapy antibodies are well on their way to showing significant benefits for patients with these diseases. This review summarizes the current knowledge of modern methods used in selected pediatric malignancies and presents therapies that may hold promise for the future.

Verified
Journal Article
Open access
PDF file
KPKinga Panuciak
Kinga Panuciak
ENEmilia Nowicka
Emilia Nowicka
AMAngelika Mastalerczyk
Angelika Mastalerczyk
Joanna ZawitkowskaJoanna Zawitkowska
Joanna Zawitkowska
MNMaciej Piotr Niedźwiecki
Maciej Piotr Niedźwiecki
MLMonika Lejman
Monika Lejman
Recent years have brought significant progress in the treatment of B-cell acute lymphoblastic leukemia (ALL). This was influenced by both the improved schemes of conventionally used therapy, as well as the development of new forms of treatment. As a consequence, 5-year survival rates have increased and now exceed 90% in pediatric patients. For this reason, it would seem that everything has already been explored in the context of ALL. However, delving into its pathogenesis at the molecular level shows that there are many variations that still need to be analyzed in more detail. One of them is aneuploidy, which is among the most common genetic changes in B-cell ALL. It includes both hyperdiploidy and hypodiploidy. Knowledge of the genetic background is important already at the time of diagnosis, because the first of these forms of aneuploidy is characterized by a good prognosis, in contrast to the second, which is in favor of an unfavorable course. In our work, we will focus on summarizing the current state of knowledge on aneuploidy, along with an indication of all the consequences that may be correlated with it in the context of the treatment of patients with B-cell ALL.

18 March 2022 in Cancers
Verified
Journal Article
Open access
PDF file
JDJustyna Derebas
Justyna Derebas
KPKinga Panuciak
Kinga Panuciak
MMMikołaj Margas
Mikołaj Margas
Joanna ZawitkowskaJoanna Zawitkowska
Joanna Zawitkowska
MLMonika Lejman
Monika Lejman
One of the most common cancer malignancies is non-Hodgkin lymphoma, whose incidence is nearly 3% of all 36 cancers combined. It is the fourth highest cancer occurrence in children and accounts for 7% of cancers in patients under 20 years of age. Today, the survivability of individuals diagnosed with non-Hodgkin lymphoma varies by about 70%. Chemotherapy, radiation, stem cell transplantation, and immunotherapy have been the main methods of treatment, which have improved outcomes for many oncological patients. However, there is still the need for creation of novel medications for those who are treatment resistant. Additionally, more effective drugs are necessary. This review gathers the latest findings on non-Hodgkin lymphoma treatment options for pediatric patients. Attention will be focused on the most prominent therapies such as monoclonal antibodies, antibody–drug conjugates, chimeric antigen receptor T cell therapy and others.

30 January 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
PPPaweł Pawlik
Paweł Pawlik
PZPrzemysław Zaroda
Przemysław Zaroda
PDPaweł Dąda
Paweł Dąda
PNPatrycja Niewinna
Patrycja Niewinna
MŻMichał Żuchowski
Michał Żuchowski
KPKinga Panuciak
Kinga Panuciak
Ingrown toenails, clinically known as onychocryptosis, represent a prevalent nail pathology. The clinical manifestation involves symptoms typical for a foreign body reaction and in severe cases, tissue hypertrophy with complications may occur. Key risk factors include improper nail care, trauma, obesity, tight footwear, poor foot hygiene, and genetic predisposition. The condition predominantly affects individuals between the first and the third decades of life and older adults, with a predilection for the great toe, especially the lateral skin fold. The Heifetz and Scholz classifications delineate the stages of ingrown toenails based on severity. Therapeutic approaches range from conservative procedures, such as taping, dental floss, gutter treatment, cotton nail cast, braces and super elastic wire to surgical interventions like partial or total nail avulsion, matricectomy and advanced techniques like the Vandebos procedure or the Winograd procedure. Although many studies have analysed available treatment methods, there is no consensus among specialists regarding the best therapeutic strategy. Complications include paronychia, infection, and scarring. A comprehensive therapeutic approach should consider clinical severity, patient preferences, and both conservative and surgical interventions, emphasizing the importance of larger randomized clinical trials to establish definitive guidelines.

12 February 2024 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
PDF file
KKKlaudia Kowalczyk
Klaudia Kowalczyk
PLPatryk Lasek
Patryk Lasek
NTNatalia Trąbka
Natalia Trąbka
PBPaulina Binkowska
Paulina Binkowska
GDGabriela Demidowicz
Gabriela Demidowicz
KPKinga Panuciak
Kinga Panuciak
Introduction: In recent years, multiple publications underscored many beneficial properties associated with medical marihuana. Its current applications encompass pain relief, multiple sclerosis, the treatment of anxiety disorders, Dravet syndrome and other. It can potentially extent to the treatment of patients with fibromyalgia or in people with diabetic complications. The expansive potential of medical cannabis in the prevention and treatment of many diseases is seen in its complex and multidirectional mechanisms of action. Medical marihuana has impact on cannabinoid receptors, and it exerts effects through many other molecular targets. Aim of the study: This review seeks present mechanisms of action of medical marihuana and explore its potential therapeutic targets. Materials and methods: A comprehensive review of literature available in the PubMed and Google Scholar databases was performed, using the following keywords: "medical marihuana", "medical cannabis", "medical marihuana mechanism of action", "therapeutic targets of medical marihuana", "endocannabinoid system", “medical marihuana in pain treatment”, “medical marihuana amygdala body”, “medical marihuana serotonin receptors”. Conclusions: Medical marihuana emerges as a promising candidate in the treatment of many diseases and common condition. However, further research is imperative to ascertain the effects of the drug and transform it into an effective medication which maximizes benefits and minimalizes side effects.